Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | ASGR1 | P07306 | 1/20 | 0.31 |
| ▸ | REN | P00797 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL626316 | 1.00 | AAK1 (0.39) | AAK1MMP13MEN1GAAKMT2A | |
| SCHEMBL16972355 | 1.00 | AAK1 (0.39) | AAK1MMP13MEN1GAAKMT2A | |
| SCHEMBL9447853 | 0.86 | MMP13 (0.38) | AAK1MMP13MEN1GAAKMT2A | |
| SCHEMBL27908634 | 0.85 | MMP13 (0.39) | AAK1MMP13MEN1GAAKMT2A | |
| SCHEMBL7401175 | 0.85 | MMP13 (0.39) | AAK1MMP13MEN1GAAKMT2A | |
| SCHEMBL1162878 | 0.85 | MMP13 (0.39) | AAK1MMP13MEN1GAAKMT2A | |
| SCHEMBL1273585 | 0.85 | MMP13 (0.39) | AAK1MMP13MEN1GAAKMT2A | |
| SCHEMBL953166 | 0.85 | MMP13 (0.39) | AAK1MMP13MEN1GAAKMT2A | |
| SCHEMBL7401177 | 0.85 | MMP13 (0.39) | AAK1MMP13MEN1GAAKMT2A | |
| SCHEMBL2480210 | 0.85 | MMP13 (0.36) | AAK1MMP13MEN1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-07-29 | — | — | US | disclosed |
| US-20240400617-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-12-05 | — | — | US | disclosed |
| CN-118324664-A | Serine derivative preparation method | 四川鸿日医药科技有限公司 | 2024-07-12 | — | — | CN | disclosed |
| CN-109563126-B | Proteasome inhibitors | 马克斯-普朗克科学促进学会 | 2023-06-16 | — | — | CN | disclosed |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
| EP-3464321-B1 | PROTEASOME INHIBITORS | MAX PLANCK GESELLSCHAFT (DE) | 2023-01-25 | — | — | EP | disclosed |
| CN-111333528-B | Synthesis method of multi-configuration O-phenyl-serine compound | 苏州爱玛特生物科技有限公司 | 2022-10-21 | — | — | CN | disclosed |
| EP-4043478-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITING ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2022-08-17 | — | — | EP | disclosed |
| US-11345724-B2 | Proteasome inhibitors | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2022-05-31 | — | — | US | disclosed |
| US-20200325171-A1 | PROTEASOME INHIBITORS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2020-10-15 | — | — | US | disclosed |
| US-20120252778-A1 | PYRAZOLO PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2012-10-04 | — | — | US | disclosed |
| CN-102639513-A | Sphingosine kinase inhibitors | MERCK PATENT GMBH | 2012-08-15 | — | — | CN | disclosed |
| WO-2012021796-A2 | NOVEL CYCLOSPORIN DERIVATIVES FOR THE TREATMENT AND PREVENTION OF A VIRAL INFECTION | S&T GLOBAL, INC. (US) | 2012-02-16 | — | — | WO | disclosed |
| US-20110275673-A1 | INHIBITORS OF SPHINGOSINE KINASE 1 | GENZYME CORPORATION | 2011-11-10 | — | — | US | disclosed |
| WO-2011082732-A1 | SPHINGOSINE KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2011-07-14 | — | — | WO | disclosed |
| US-20110034469-A1 | Heterocyclic Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-02-10 | — | — | US | disclosed |
| US-20100093704-A1 | NOVEL PSYCHOTROPIC AGENTS HAVING GLUTAMATE NMDA ACTIVITY | RAMOT AT TEL-AVIV UNIVERSITY LTD (IL) | 2010-04-15 | — | — | US | disclosed |
| WO-2010033701-A2 | INHIBITORS OF SPHINGOSINE KINASE 1 | GENZYME CORPORATION (US) | 2010-03-25 | — | — | WO | disclosed |
| US-6180611-B1 | INHIBITORS OF MATRIX METALLOPROTEINASES AND TUMOR NECROSIS FACTOR | DARWIN DISCOVERY, LTD. (GB) | 2001-01-30 | — | — | US | disclosed |
| US-5994312-A | Peptidyl compounds | DARWIN DISCOVERY, LTD. (GB) | 1999-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034469-A1 | Heterocyclic Compound | BIRC5, XIAP, BIRC2 | AAK1 2940/4885MMP13 4138/4885MEN1 363/4885 |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | AAK1 928/4885MMP13 3770/4885MEN1 492/4885 |
| US-20240400617-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | AAK1 928/4885MMP13 3770/4885MEN1 492/4885 |
| US-20200325171-A1 | PROTEASOME INHIBITORS | PSMB1, PSMB2, PSMB5 | AAK1 3401/4885MMP13 3814/4885MEN1 2770/4885 |
| US-20110275673-A1 | INHIBITORS OF SPHINGOSINE KINASE 1 | SPHK1, SPHK2, S1PR1 | AAK1 72/4885MMP13 1916/4885MEN1 2381/4885 |
| US-20120252778-A1 | PYRAZOLO PYRIMIDINE DERIVATIVES | THPO, P2RX3, P2RX5 | AAK1 1200/4885MMP13 3473/4885MEN1 4318/4885 |
| US-20100093704-A1 | NOVEL PSYCHOTROPIC AGENTS HAVING GLUTAMATE NMDA ACTIVITY | GRIN1, GRIN2A, GRIN2B | AAK1 696/4885MMP13 4627/4885MEN1 3397/4885 |
| US-11345724-B2 | Proteasome inhibitors | PSMB1, PSMB2, PSMB5 | AAK1 3289/4885MMP13 3616/4885MEN1 3000/4885 |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | KRAS, NRAS, HRAS | AAK1 928/4885MMP13 3770/4885MEN1 492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.